J&J ducks out of Bavarian Nordic vaccine partnerships

Johnson & Johnson has halved the size of its collaboration with Bavarian Nordic on vaccine development, jettisoning its stake in shots targeting human papillomavirus (HPV) and hepatitis

Race for hepatitis B drug intensifies as Antios raises $96m ...

Antios has raised $96 million in Series B financing to support the ongoing phase 2 development of its hepatitis B drug candidate, ATI-2173.

Ionis deal delivers for GSK as HBV drug hits the mark in pha...

An antisense drug developed by GlaxoSmithKline has been shown to suppress the hepatitis B virus (HBV) in a phase 2 trial, raising hopes of a “functional cure” for the widesprea

Roche swoops on Dicerna’s gene-silencing hepatitis B drug

Janssen and Bavarian Nordic sign $836m deal on Hep B and HIV...

Janssen has signed a new deal with Bavarian Nordic worth up to $836 million to develop target vaccines for hepatitis B and HIV.

Gilead ordered to pay Merck & Co $2.54 bn by US court

Ruling relates to infringement of patents held by Merck subsidiary